Literature DB >> 11809696

X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance.

Shin-Young Park1, Wing Lam, Yung-chi Cheng.   

Abstract

X-ray repair cross-complementing gene I protein (XRCC1) in complex with DNA polymerase beta, DNA ligase III, and poly(ADP-ribose) polymerase is important in the base excision repair process. Previously, we isolated camptothecin (CPT)-resistant cell lines (KB100 and KB300) from the human epidermoid carcinoma cell line KB by exposure to CPT. From these CPT-resistant cell lines, their revertants (KB100(rev) and KB300(rev)), which lost most of their CPT-resistant phenotype during passage in the absence of CPT, were established. In this study, we found the expression levels of XRCC1 protein in KB100 and KB300 were > or =5-fold more than in their respective revertant cell lines, whereas there was no difference in the expression of XRCC1-associated proteins such as DNA polymerase beta, DNA ligase III, poly(ADP-ribose) polymerase, and apurinic/apyrimidinic endonuclease. The degree of CPT resistance was relatively correlated with the XRCC1 protein amount. We also found XRCC1 gene amplification in CPT-resistant KB100 and KB300 cell lines. To confirm a correlation between overexpression of XRCC1 and CPT resistance, we transfected the XRCC1 gene into KB100(rev) and obtained two different transfected cell lines (clones 14 and 16). The expression levels of XRCC1 in the transfected cell lines were higher than in KB100(rev) but lower than in KB100 with no difference in XRCC1-associated protein expression levels. Resistance to CPT in transfected cell lines was 2-2.5-fold higher than in KB100(rev) in regard to growth inhibition and 4-fold higher with respect to clonogenicity. Transfected cell lines also showed increased resistance to other topoisomerase I poisons. However, the cytotoxicity of VP-16 and cisplatin was similar in both the transfected cells and KB100(rev). Similar to our CPT-resistant cell lines, the resistance of transfected cell lines was reversed by treatment with 3-aminobenzamide. These results indicate that CPT resistance in our cells could be partly attributable to the overexpression of XRCC1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809696

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Potential protein partners for the N-terminal domain of human topoisomerase I revealed by phage display.

Authors:  Agata M Trzcińska; Agnieszka Girstun; Agnieszka Piekiełko; Barbara Kowalska-Loth; Krzysztof Staroń
Journal:  Mol Biol Rep       Date:  2002-12       Impact factor: 2.316

Review 2.  Overview of base excision repair biochemistry.

Authors:  Yun-Jeong Kim; David M Wilson
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

Review 3.  Repair of topoisomerase I-mediated DNA damage.

Authors:  Yves Pommier; Juana M Barcelo; V Ashutosh Rao; Olivier Sordet; Andrew G Jobson; Laurent Thibaut; Ze-Hong Miao; Jennifer A Seiler; Hongliang Zhang; Christophe Marchand; Keli Agama; John L Nitiss; Christophe Redon
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

4.  False cell lines: The problem and a solution.

Authors:  John R Masters
Journal:  Cytotechnology       Date:  2002-07       Impact factor: 2.058

5.  WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.

Authors:  Markus Christmann; Maja T Tomicic; Christopher Gestrich; Wynand P Roos; Vilhelm A Bohr; Bernd Kaina
Journal:  DNA Repair (Amst)       Date:  2008-10-15

6.  The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.

Authors:  Mehmet Artac; Hakan Bozcuk; Sacide Pehlivan; Songül Akcan; Mustafa Pehlivan; Tugce Sever; Mustafa Ozdogan; Burhan Savas
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-12       Impact factor: 4.553

Review 7.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

8.  Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

Authors:  Anand G Patel; Karen S Flatten; Paula A Schneider; Nga T Dai; Jennifer S McDonald; Guy G Poirier; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

9.  High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma.

Authors:  Mei-Kim Ang; Mihir R Patel; Xiao-Ying Yin; Sneha Sundaram; Karen Fritchie; Ni Zhao; Yufeng Liu; Alex J Freemerman; Matthew D Wilkerson; Vonn Walter; Mark C Weissler; William W Shockley; Marion E Couch; Adam M Zanation; Trevor Hackman; Bhishamjit S Chera; Stephen L Harris; C Ryan Miller; Leigh B Thorne; Michele C Hayward; William K Funkhouser; Andrew F Olshan; Carol G Shores; Liza Makowski; D Neil Hayes
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

10.  Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.

Authors:  Salomé Paillas; Florence Boissière; Fréderic Bibeau; Amélie Denouel; Caroline Mollevi; Annick Causse; Vincent Denis; Nadia Vezzio-Vié; Laetitia Marzi; Cédric Cortijo; Imade Ait-Arsa; Nadav Askari; Philippe Pourquier; Pierre Martineau; Maguy Del Rio; Céline Gongora
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.